The presented profiling of sEVs from MPE fluid of NSCLC patients with advanced disease, where targeted therapy is often used, revealed feasibility to monitor the tumor-associated membrane receptors EGFR, HER2, and IGF-1R. Here, ERBB2 is linked to non-small cell lung carcinoma.